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ABSTRACT To investigate the transmission of novel infectious agents by blood transfusion, we studied changes in the virome
composition of blood transfusion recipients pre- and posttransfusion. Using this approach, we detected and genetically charac-
terized a novel human virus, human hepegivirus 1 (HHpgV-1), that shares features with hepatitis C virus (HCV) and human
pegivirus (HPgV; formerly called GB virus C or hepatitis G virus). HCV and HPgV belong to the generaHepacivirus and Pegivi-
rus of the family Flaviviridae. HHpgV-1 was found in serum samples from two blood transfusion recipients and two hemophilia
patients who had received plasma-derived clotting factor concentrates. In the former, the virus was detected only in the post-
transfusion samples, indicating blood-borne transmission. Both hemophiliacs were persistently viremic over periods of at least
201 and 1,981 days. The 5= untranslated region (UTR) of HHpgV-1 contained a type IV internal ribosome entry site (IRES),
structurally similar to although highly divergent in sequence from that of HCV and other hepaciviruses. However, phylogenetic
analysis of nonstructural genes (NS3 and NS5B) showed that HHpgV-1 forms a branch within the pegivirus clade distinct from
HPgV and homologs infecting other mammalian species. In common with some pegivirus variants infecting rodents and bats,
the HHpgV-1 genome encodes a short, highly basic protein upstream of E1, potentially possessing a core-like function in packag-
ing RNA during assembly. Identification of this new human virus, HHpgV-1, expands our knowledge of the range of genome
configurations of these viruses andmay lead to a reevaluation of the original criteria by which the generaHepacivirus and Pegivi-
rus are defined.
IMPORTANCE More than 30million blood components are transfused annually in the United States alone. Surveillance for infec-
tious agents in the blood supply is key to ensuring the safety of this critical resource for medicine and public health. Here, we
report the identification of a new and highly diverse HCV/GB virus (GBV)-like virus from human serum samples. This new vi-
rus, human hepegivirus 1 (HHpgV-1), was found in serum samples from blood transfusion recipients, indicating its potential for
transmission via transfusion products. We also found persistent long-termHHpgV-1 viremia in two hemophilia patients.
HHpgV-1 is unique because it shares genetic similarity with both highly pathogenic HCV and the apparently nonpathogenic
HPgV (GBV-C). Our results add to the list of human viruses and provide data to develop reagents to study virus transmission
and disease association and for interrupting virus transmission and new human infections.
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Transfusion of blood or blood-derived products can save livesand improve health but requires safety measures for prevent-
ing bystander transmission of infectious agents. Exclusion of
blood products contaminated with infectious agents includes rig-
orous testing for pathogenic viruses (1, 2). The unusually high
infection prevalence of hepatitis C virus (HCV), HBV, andHIV in
hemophilia patients and other transfusion recipients could have
been prevented by earlier identification of these viruses and devel-
opment of accurate diagnostic assays (3–8). Advances in sequenc-
ing platforms have revolutionized identification of new viruses (9)
and have been widely adopted for identification and characteriza-
tion of viruses that infect humans and animals (10–15). Genetic
characterization of new viruses is a first crucial step toward their
molecular and biological characterization. Sequence data of a new
virus not only help in estimating its biological properties but also
enable development of molecular reagents that can be used for
molecular diagnostics and epidemiological and clinical investiga-
tions of their transmission and disease associations (9).
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HCV infects ~200 million people worldwide and represents a
genetically diverse group of human RNA viruses with similar bi-
ological properties. HCV typically persists, with only 20 to 30% of
cases resolving after acute infection (16, 17). HCV is a global
pathogen, as a large proportion of untreated individuals progress
to severe liver disease, cirrhosis, and hepatocellular carcinoma.
HCV therapies based on antivirals that directly target HCV repli-
cation are expensive, and prevention of new virus infections re-
mains the priority (18). The identification of HCV in 1989 (19)
was crucial for development of diagnostic assays to arrest its
spread through transfusion and other parenteral routes of expo-
sure. Other human viruses genetically related to HCV include
human pegivirus (HPgV, formerly named GB virus C or hepatitis
G virus) and a growing range of related viruses currently known to
infect horses, rodents, bats, and monkeys (reviewed in references
20 and 21). HPgV causes widespread human infection (1 to 4% of
healthy blood donors) that can persist for years with no clinical
symptoms (22).
Identification of natural infection with nonprimate hepacivi-
rus (NPHV), first in dogs (initially termed canine hepacivirus)
and subsequently in horses, was the first indication of a wider host
range for hepacivirus infections (23–25). More recently, identifi-
cation of a diverse range of viruses found in bats, rodents, andOld
World primates further expanded the host range of hepaciviruses
(11, 12, 26–28). Similarly, several novel pegiviruses have recently
been identified, with a single report of such viruses in bats in 2010
(29), followed by several recent reports of novel viruses in horses,
rodents, and bats (11, 12, 26, 27, 30). These new discoveries have
fundamentally revised our knowledge of viral diversity and host
ranges of hepaciviruses and pegiviruses (20). However, so far, the
only two viruses known to infect humans are HCV and HPgV.
Here, we describe first identification of a highly divergent human
virus, human hepegivirus 1 (HHpgV-1), that shares attributes of
both HCV and HPgV.
RESULTS
Virome analysis of transfusion recipients. To characterize the
changes in serum virome compositions of transfusion recipients,
we studied pretransfusion and posttransfusion serum samples
from subjects enrolled in the Transfusion-Transmitted Viruses
Study (TTVS) from July 1974 through June 1980. One pre- and
one posttransfusion serum sample from 44 individuals were en-
riched for viral nucleic acids and studied by unbiased amplifica-
tion and Illumina sequencing (11). A total of 154 and 119 million
readswere generated from the pretransfusion and posttransfusion
samples, respectively. The descriptive statistics mean, standard
deviation (SD), and median were calculated for viral abundance.
The viral abundance at pretransfusion and the rate at posttrans-
fusion were compared by paired Wilcoxon rank sum test. Com-
parison of posttransfusion samples with pretransfusion samples
revealed significant increase in the numbers of total virus reads
(P  0.009) and anellovirus reads (P  0.007) after transfusion
(Fig. 1). To understand the nature and composition of increased
anellovirus sequences, comparative analysis was done for all virus
populations (virome) in pre- and posttransfusion samples from
six TTVS subjects that showed nonsignificant increases in the
numbers of normalized anellovirus reads and six TTVS subjects
that showed 10-fold increases in the numbers of anellovirus
virus reads in the posttransfusion samples. Our analysis shows
that the majorities of increased anellovirus reads were new geno-
types or species that were genetically different from those that
existed in individuals before transfusion. However, we also no-
ticed persistence of a proportion of anellovirus sequences that
were genetically similar among pre- and posttransfusion samples
(Fig. 1). Together, these findings indicate that these subjects were
infected by both stable and fluctuating anellovirus populations
that can exist as coinfections. Of the total virus reads, approxi-
mately 40% of the reads remained unclassified due to their low
similarity to known viruses (E value range, 102 to 106). Further
analysis of these unclassified reads revealed the presence of a novel
flavivirus in two posttransfusion samples.
Identification of HHpgV-1. Bioinformatic analysis of se-
quence data of two serum samples, TTVS-772 and TTVS-790,
both collected after blood transfusion, indicated the presence of a
novel flavivirus, showing only distant sequence homology toHCV
andHPgV. PCR assays were used to confirm the presence of these
flavivirus-like sequences in a fresh aliquot of the original serum
samples. After initial analysis of data, both samples, TTVS-772
and TTVS-790, were subjected tomore in-depth sequencing, gen-
erating 100 million single-end Illumina reads. All sequence
reads that mapped to genomes of known hepaciviruses and pegi-
viruses and showed protein similarity (E value  0.0001) with
different genomic regions of these viruses were connected using
PCRs of intervening genomic fragments and Sanger dideoxy se-
quencing. Finally, the complete polyprotein coding region of hu-
man hepegivirus 1 (HHpgV-1) present in TTVS-790 was se-
quenced atmore than 4 coverage, and the genomic termini were
acquired using random amplification of cDNA ends (RACE) (23),
yielding a 9,538-nucleotide genome of the new virus, HHpgV-1.
Polyprotein-coding region of HHpgV-1. A continuous read-
ing frame spanned most of the HHpgV-1 genome, with a termi-
nation codon at position 9501 (Fig. 2). Predicting the start of the
virus polyprotein was more problematic because several in-frame
ATG (methionine) triplets were present at the 5= end of the
HHpgV-1 sequence. Of these, those at positions 195 and 204 di-
verged from the optimal Kozak motif (GTTC|ATG|GAGG and
AGGGC|ATG|CCCA, respectively). The codon at position 330
had an optimal sequence (GCAAC|AUG|GGGU), the fourth (po-
sition 519) was suboptimal (CCGGU|AUG|UGTT), and the fifth
(position 587) fell within a region of identifiable protein sequence
homology to the E1 sequence of pegiviruses. Determination of the
RNA structure of the 5= untranslated region (UTR) (see below)
provided separate evidence that the (third) ATG triplet at position
330 was the genuine initiating codon, and this has been assumed
in the analysis of protein cleavage sites below.
Evolutionary relatedness of HHpgV-1 with hepaciviruses
and pegiviruses. The translated ORF of HHpgV-1 was aligned
with pegivirus and hepacivirus sequences from humans and
chimpanzees (HPgV, simian pegivirus infecting chimpanzees
[SPgVtro], and HCV), Old World primates (SPgV-OWM and
SHcV-OWM), viruses formerly described as GB virus A (GBV-A)
and GBV-B from New World primates (SPfV-NWM and SHcV-
NWM), rodent variants from rats andmice (RPgV andRHcV-1 to
RHcV-3) and horses (EPgV-1, EPgV-2, and NPHV), and several
different groups of pegiviruses and hepaciviruses from bats
(BPgV-1 to BPgV-5 and BHcV-1 to BHcV-4).
Translated amino acid sequences could be readily aligned over
most of the genome of pegiviruses and the nonstructural gene
region of hepaciviruses. Evolutionary relationships of HHpgV-1
with other groupswere determined by phylogenetic analysis of the
Kapoor et al.
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more highly conserved NS3- and NS5B-encoding regions. Trees
from the two regions were congruent in which the HHpgV-1 se-
quence was distinct from all pegivirus and hepacivirus sequences
published to date (Fig. 3). In both regions, sequences split into
separate clades corresponding to classifications as hepaciviruses
and pegiviruses. Within the latter clade, two genetically distinct
lineages were apparent (groups 1 and 2); group 1 comprised vari-
ants from humans, primates, horses, and bat lineages 1, 4, and 5,
while the HHpgV-1 sequence and variants from rodents and bat
lineages 2 and 3 fell into group 2.
Prediction of HHpgV-1 polyprotein cleavage sites. The posi-
tions of gene boundaries of HHpgV-1 were predicted using two
approaches. Translated amino acid sequences in the 5= structural
gene region were submitted to the Signal P 4.0 server to identify
signalase cleavage sites used by other pegiviruses to process struc-
tural genes (Fig. 2). This revealed three potential cleavage sites
comparable in position to those previously identified for equine
pegiviruses and in part to those in the annotation of SPgV-NWM.
However, in addition to the E1, E2, and X proteins, HHpgV-1 was
predicted to include an additional 65-amino-acid, cysteine-rich
protein upstream of E1. Additional coding regions have been pre-
viously identified in rodent PgV (12) and labeled “VR” in the
group 2 bat pegiviruses (lineages 2 and 3) (26). Y or VR proteins
were highly variable in size and showed no identifiable sequence
similarity to each other. The sequence from HHpgV-1 did, how-
ever, share the property of being highly basic with several posi-
FIG 1 Virome analysis of TTVS pre- and posttransfusion samples. (Top) Statistical analysis of total virus sequences (left), anellovirus sequences (middle), and
virus-like unclassified sequences (right) in pre- and posttransfusion samples. (Bottom)Metagenomic binning of all viruses sequences in pre- and posttransfusion
samples from twelve TTVS subjects. Red arrows represent pre- and posttransfusion sample pairs that were similar in amount of total virus sequences, and purple
arrows represent pre- and posttransfusion sample pairs where posttransfusion samples had significantly larger amounts of total virus sequences.
Identiﬁcation of Human Hepegivirus 1
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tively charged residues (pI 8.6) (Fig. 2), comparable to previously
analyzed bat sequences (pI 8.2 to 9.1) and RPgV (pI 10.1). The Y
and VR proteins, differed, however, in their predicted locations,
with rodent and bat Y/VR proteins possessing a predicted sig-
nalase cleavage site at the N-terminus that may re-locate the pro-
tein through the endoplasmic reticulum (ER). In contrast, the Y
protein of HHpgV-1 possessed no such initial translocating se-
quence, which potentially indicates a cytoplasmic location for the
protein. This processing resembles that of the core proteins of
hepaciviruses, which functions in RNA packaging and virion for-
mation. Although considerably shorter than the processed HCV
protein, the Y protein of the HHpgV-1 sequence may have a sim-
ilar function.
The E2 protein contained 11 potential N-linked glycosylation
sites, a greater number than recorded for other pegiviruses; addi-
tional sites were detected in E1 (n  3) and X (n  1). E2 addi-
tionally contained a potential O-linked site at position 422
(Fig. 2). This pattern of heavy glycosylation, comparable in extent
to that of HCV and other hepaciviruses, was distinct from the
infrequent sites recorded for human and other group 1 pegi vi-
ruses. For prediction of cleavage sites between nonstructural pro-
teins, there was sufficient similarity between the HHpgV-1 and
other pegivirus sequences with annotated sites for homologous
positions to be identified (Fig. 2). Proteins predicted in the NS
region of HHpgV-1 were comparable in position and size to those
of other pegiviruses and hepaciviruses (Fig. 2).
Sequence divergence between sequences of HHpgV-1 and
other pegiviruses aligned over the genomewas high, ranging from
61 to 65%with group 1 pegivirus sequences and 58% to 60%with
group 2 in the structural gene region (Table 1). This corresponded
to amino acid distance ranges of 68 to 79% and 69 to 71% in this
genome region. The nonstructural gene regions were better con-
served, with group 1 and 2 nucleotide distance ranges of 57 to 59%
and 55%betweenHHpgV-1 and group 1 and 2 sequences, respec-
tively, and 68 to 69%and 62 to 64%amino acid distances for those
two groups (Table 2). As implied by these results, sequence diver-
gence was distributed throughout the pegivirus genome, with
40% minimum amino acid sequence divergence values of win-
dowed fragment between HHpgV-1 and each lineage of other
pegiviruses (Fig. 4). Highest divergence was observed in the struc-
tural gene regions and NS4B/NS5A, while minimum values were
found in association with functionally conserved polymerase and
helicase motifs in NS5B and NS3.
Prediction of 5= UTR RNA structure. The separate grouping
of pegiviruses into two main clades in the coding region was re-
produced in sequence relationships of the 5= UTR. All sequences
of group 1 viruses could be aligned and possessed predicted RNA
secondary structures closely matching that of GBV-A and the re-
cently predicted structure of equine pegivirus (11). Surprisingly,
5= UTR sequences of group 2 pegiviruses showed no homology to
those of group 1 but nevertheless could be alignedwith each other.
Although highly divergent in sequence from all other known viral
5= UTR sequences, certain motifs matched those of members of
the Hepacivirus genus, including the highly conserved sequence
TACAGCCTGATAGGGT at position 274. The sequence lies
within domain IIIe (pseudoknot region) in the hepacivirus inter-
nal ribosome entry site (IRES). Accordingly, the sequence of
HHpgV-1 was structurally aligned to hepacivirus 5= UTR se-
quences, an analysis that revealed the presence of a typical type IV
IRES (Fig. 5) and upstream stem-loops corresponding in position,
shape and size to domains I and II of HCV.However, themiR-122
seed match sequence (ACACUCCA) was absent in the 5= UTR
sequence of HHpgV-1 and all other known pegiviruses. As antic-
ipated based on their sequence homology, the other group 2 pegi-
viruses have similarly structured type IV IRES elements despite
their substantial sequence divergence from each other (data not
shown). In this RNA structuremodel of theHHpgV-1 5=UTR, the
third ATG at position 330 that possesses the optimal Kozak se-
quence is located 11 bases downstream from the pseudoknot in
domain IV and, by analogy, is the most plausible initiating codon
for HHpgV-1.
GORS. Thermodynamic folding analysis of the HHpgV-1 se-
quence revealed a mean 7.6% free energy difference between its
minimum folding energy and that of sequence order-randomized
FIG 2 Genome organization and polyprotein cleavage sites of HHpgV-1. The positions of cleavage sites of the viral NS2 (white triangles) andNS3 protease (grey
triangles) were predicted by alignment and homology to sites in the nonstructural genes previously characterized in other pegiviruses and hepaciviruses. Cleavage
sites in structural gene regions (black triangles) were independently predicted using the SignalP 4.1 server. Predicted N-linked glycosylation sites in envelope
proteins are depicted by vertical arrows; the single predicted O-linked glycosylation site is indicated with a blue arrow. The amino acid sequence of the predicted
Y protein is shown above the genome diagram. Charged residues and cysteines are in color.
Kapoor et al.
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controls (MFED), an observation consistent with the presence of
genome-scale ordered RNA structure (GORS) in the HHpgV-1
sequence (23). However, thisMFED value was lower than those of
the group 1 viruses HPgV (mean, 11.7%; standard deviation,
0.7%), SPgV-OWM (10.9%  1.3%), SPgV-NWP (11.8% 
0.4%), EPgV-1 (10.4%), and EPgV-2 (11.9%). However, the
MFED value of HHpgV-1 was comparable to MFED values of
group 2 pegiviruses (7.9% to 8.8%) (Table 3).
HHpgV-1 infections, prevalence, and coinfections.To deter-
mine the prevalence and nature ofHHpgV-1 infection in humans,
we tested pretransfusion and posttransfusion serum samples from
46 and 116 TTVS subjects, respectively. We also tested 1 to 5
longitudinally collected serum samples from 106Multicenter He-
mophilia Cohort Study (MHCS) subjects. Only two posttransfu-
sion samples from TTVS subjects were positive for HHpgV-1
RNA, TTVS-772 and TTVS-790. The HHpgV-1-positive serum
sample TTVS-772 was collected from a subject 17 days posttrans-
fusion. A sample from the same individual collected one day be-
fore transfusion (TTVS-0927) and another collected 281 days af-
ter transfusion (TTVS-1095) tested negative for the virus. The
FIG 3 Maximum-likelihood phylogenetic analysis of the NS3 and NS5B genes of HHpgV-1 (tt790) and available complete genome sequences of other
hepaciviruses and pegiviruses infecting different mammalian species. Phylogenetic analysis of each data set used 100 bootstrap resamplings to determine
robustness of grouping; values are shownonbranches. Abbreviations:HcV, hepacivirus; PgV, pegivirus;OWM,OldWorldmonkey;NWM,NewWorldmonkey;
R, rodent; B, bat; Bo, bovine; NPHV, nonprimate hepacivirus. Lineage numbers are shown in parentheses.
Identiﬁcation of Human Hepegivirus 1
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HHpgV-1-positive serum sample TTVS-790 was collected at
7 days posttransfusion. A sample from the same individual col-
lected one day before transfusion (TTVS-1608) and another col-
lected at 241 days after transfusion (TTVS-791) tested negative for
HHpgV-1 RNA. These results indicate transient viremia of
HHpgV-1 in posttransfusion samples followed by virus clearance
in both the infected patients.
Of the 106 MHCS subjects, multiple samples from only two
subjects, M3127 and M4287, were positive for HHpgV-1 RNA.
The two adjacent samples from subject M3127 positive for
HHpgV-1 were collected 201 days apart, while a sample collected
144 days before the first positive sample and two other samples
collected at days 560 and 3461 after the second positive sample
remained negative for HHpgV-1 infection. For the second
HHpgV-1-positive MHCS subject (M4287), four longitudinal
samples were available for this study and all were positive for
HHpgV-1. The latter three of these four samples were collected at
399, 742, and 1,981 days after the first sample collection day. These
results indicate persistence of HHpgV-1 viremia for more than
201 and 1,981 days (5.4 years) in these two MHCS subjects.
All PCR products were sequenced from both directions, to
confirm results and to study the genetic diversity among different
HHpgV-1 variants. Phylogenetic analysis confirmed the close ge-
netic relatedness amongHHpgV-1 variantswithin their respective
MHCS and TTVS subjects (Fig. 6). Sequences were highly con-
served, with substitutions being restricted largely to synonymous
sites. However, by analogy to other pegiviruses and hepaciviruses,
greater variability is likely elsewhere in the genome. Coinfections
with HCV and HPgV were determined by viremia screening of
HHpgV-1-positive samples for for HPgV and HCV. Three of the
fourHHpgV-1-infected subjects were found to be coinfected with
HCV (genotype 1a in two subjects and 1b in one subject). All
HHpgV-1 subjects and their respective samples remained nega-
tive for HPgV coinfection.
DISCUSSION
Weused an unbiased (sequence-independent) virus discovery ap-
proach (9) to characterize known as well as unknown viruses that
can pose a risk of transfusion transmission. We studied longitu-
dinal pre- and posttransfusion samples from TTVS subjects for
comparative analysis of changes in virome compositions after
transfusion. The number of virus reads, particularly of anellovi-
ruses, significantly increased after transfusion (Fig. 1). TTV spe-
cies were studied in transfusion recipients earlier (31, 32), but the
cross section design and low-depth sequencing approach used in
previous studies were not suitable for characterizing the compo-
sitional changes in TTV populations over time. There can be sev-
eral reasons for the changes we observed in the virome of transfu-
sion recipients, such as deteriorating health of subjects and new
nosocomial infections, including transfusion transmission of vi-
ruses. The presence of a novel human virus, HHpgV-1, in two
transfusion recipients was our most interesting observation. The
availability of longitudinal serum samples for TTVS subjects was
helpful in determining the nature ofHHpgV-1 infection; the virus
infection was present only in the posttransfusion samples and was
followed by clearance of viremia in both subjects. Although our
TABLE 1 Nucleotide sequence divergence of structural and nonstructural genes of HHpgV-1 and other pegiviruses
Gene region and group Lineage
Nucleotide distance (%)a
Group 1 Group 2
HHpgV-1 Ape OWM NWM Bat_ Bat_4 Bat_5 Equine_1 Equine_2 Bat_2 Bat_3 Rodent
Structural
1 Ape 63.0 18.3
OWM 61.3 43.1 18.9
NWM 63.0 52.5 53.0 43.0
Bat_ 63.4 51.6 51.4 47.5 38.4
Bat_4 64.1 55.2 55.5 56.9 57.5 41.2
Bat_5 65.2 52.5 51.7 56.5 56.4 55.4 —
Equine_1 63.9 58.3 58.2 61.5 61.1 62.7 60.1 —
Equine_2 63.3 57.0 56.9 58.5 57.4 59.5 58.0 61.3 —
2 Bat_2 59.5 60.9 60.9 62.7 61.5 62.9 60.2 62.4 59.6 9.0
Bat_3 59.3 59.5 60.4 62.9 62.5 62.8 61.3 61.7 61.3 54.8 41.9
Rodent 58.0 59.2 61.0 61.6 62.3 62.4 59.8 60.9 59.8 52.2 54.2 49.2
Nonstructural
1 Ape 59.1 15.4
OWM 59.0 37.1 16.1
NWM 59.1 46.8 47.9 36.7
Bat_ 58.6 46.6 47.0 40.0 31.4
Bat_4 58.1 51.7 51.8 51.6 50.8 32.7
Bat_5 57.4 49.8 51.2 50.5 50.6 47.2 —
Equine_1 58.7 52.9 53.6 52.3 52.0 50.8 51.6 —
Equine_2 57.8 52.6 53.1 52.5 51.9 50.8 51.0 49.4 —
2 Bat_2 54.9 54.9 55.3 55.4 54.4 54.4 54.4 55.7 55.4 5.5
Bat_3 55.3 55.2 56.3 55.8 54.9 55.3 55.4 55.4 56.4 45.4 30.8
Rodent 54.9 54.8 55.3 55.4 54.4 54.4 54.4 55.9 55.2 45.2 47.7 42.7
a Bold indicates within-group comparisons. “”, No within-group comparison made (only one group member exists).
Kapoor et al.
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results provide evidence for transfusion-mediated transmission of
HHpgV-1, further studies are necessary to verify the presence of
HpgV-1 in the transfused blood and to rule out other possible
iatrogenic infection sources over this period. Although the pres-
ence of a new viral genome in the human serum samples confirms
infection, more evidence should be sought, including seroconver-
sion of infected patients; therefore, we are developing a serological
assay for HHpgV-1 (23, 33). Considering that processing clinical
samples in a laboratory, as well as contaminated nucleic acid ex-
traction reagents, can be a potential source of divergent viruses (9,
34), we always included appropriate negative controls in all exper-
iments of this study. The control samples included in this study
were water and PBS extracted with each batch of serum samples
and also nontemplate reagent controls for reverse transcription
and screening PCR assays. Moreover, comparison of HHpgV-1
sequences amplified from different samples collected from differ-
TABLE 2 Translated amino acid sequence divergence of structural and nonstructural genes of HHpgV-1 and other pegiviruses
Gene region and group Lineage
Amino acid distance (%)
Group 1 Group 2
HHpgV-1 Ape OWM NWM Bat_ Bat_4 Bat_5 Equine_1 Equine_2 Bat_2 Bat_3 Rodent
Structural
1 Ape 74.9 10.4
OWM 74.7 44.0 14.7
NWM 76.3 61.2 61.7 43.8
Bat_ 76.3 59.5 59.4 53.4 37.9
Bat_4 79.2 64.9 64.8 68.1 68.9 44.7
Bat_5 78.3 62.3 60.1 67.6 66.9 66.4 0.0
Equine_1 78.9 67.6 68.7 75.4 75.1 77.1 72.6 0.0
Equine_2 76.8 66.1 65.7 71.4 69.3 71.4 68.9 73.5 0.0
2 Bat_2 71.4 74.6 74.0 77.8 76.6 77.5 75.8 77.9 73.9 1.0
Bat_3 70.6 73.0 72.8 77.4 76.8 75.9 75.6 76.5 74.7 66.4 46.0
Rodent 69.2 71.7 73.9 76.6 77.1 77.0 75.1 75.1 75.2 61.9 65.2 56.4
Nonstructural
1 Ape 68.5 5.4
OWM 68.6 32.7 10.4
NWM 68.9 49.2 50.5 31.5
Bat_ 69.0 49.2 49.2 37.6 25.4
Bat_4 68.6 57.0 56.3 57.8 56.6 30.1
Bat_5 67.9 55.8 56.4 56.3 56.4 51.6 0.0
Equine_1 68.6 58.9 59.6 59.3 59.0 57.1 57.4 0.0
Equine_2 68.7 58.7 59.2 60.4 59.8 56.6 57.3 53.5 0.0
2 Bat_2 62.2 62.9 64.6 65.2 64.3 63.3 64.8 64.4 65.0 0.5
Bat_3 63.3 63.8 65.4 64.9 63.9 63.7 64.8 64.8 66.0 48.1 27.9
Rodent 63.6 63.6 64.4 64.8 63.6 62.7 63.7 64.6 64.4 48.3 50.6 42.0
FIG 4 Amino acid sequence divergence between HHpgV-1 and other pegiviruses using a 240-nucleotide fragments with 24-nucleotide increments across the
virus alignment (midpoint plotted on the x axis).Within-species distances for human and simian pegiviruses were included for comparison. The divergence scan
was numbered using the AF121950 HPgV reference sequence. OWM, Old World monkey; NWP, NewWorld primate; NWM, NewWorld monkey.
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ent individuals and at different time points revealed the existence
of some diversity, concentrated at synonymous sites; the finding
of patient-specific groupings of sequences (Fig. 6) similarly argues
strongly against laboratory or reagent contamination as the
HHpgV-1 sequences.
HHpgV-1 was identified by Illumina sequencing in the post-
transfusion samples from two of the 46 originally enrolled TTVS
subjects. Subsequent specific PCR screening of posttransfusion
samples from 70 TTVS subjects failed to identify any further pos-
itive samples. HHpgV-1 was also detected only infrequently in
hemophiliacs (2 of 106 subjects). The infrequency of detection of
HHpgV-1 compared to HCV andHPgV in this risk groupmay be
explained by the fact that (i) HHpgV-1 is a much less prevalent
human infection, (ii) this virus establishes persistence less fre-
quently, or (iii) the PCR-based screeningmethod used for viremia
detection was unable to amplify sequences of more genetically
divergent variants of HpgV-1. Historically, the latter explanation
led to an underestimate of the prevalence of infection ofHCV (35)
that was only resolved when the full extent of the genotype diver-
sity of HCV was identified. Determining the incidence and prev-
alence of human HHpgV-1 infection will require additional mo-
lecular and serological studies.
The genomic organization of HHpgV-1 revealed several novel
genetic features in this new human virus. First, the 5= UTR was
nonhomologous to that of most other pegiviruses, forming a type
IV IRES, hitherto described only formembers of the generaHepa-
civirus and Pestivirus of Flaviviridae. HHpgV-1 shared sequence
motifs with other group 2 pegiviruses, despite their sequence di-
FIG 5 Predicted RNA secondary structure of the 5= UTR, based on structural mapping of the HHpgV-1 sequence to hepacivirus sequences based on an initial
seed match in domain IIIe. Stem-loops for domains I and II were predicted by Mfold.
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vergence from each other, allowing the retrospective identifica-
tion of this IRES type in all members of this pegivirus subgroup,
undocumented in the original publications (12, 26). This finding
is complementary to the earlier description of pegivirus-like IRES
sequences in three bat-associated hepaciviruses (27). As with pi-
cornaviruses (36), exchange of the translation modules between
otherwise distantly related viruses evidently occurs relatively often
in the evolutionary history of RNA viruses, although the forces
driving such modular exchanges and effects of different IRES
types on virus replication strategies and interaction with host cells
are largely unknown. However, variable dependence of different
IRES types on host translation initiation factors, such as eIF3 and
eIF-2 (37, 38), clearly influences their ability towithstand shutoff
of host cell translation mediated through stress responses or in-
duction of interferon-stimulated genes (39). Another genomic
feature of HHpgV-1 is the presence of short coding sequences
upstream of E1 (Fig. 3). This coding region encodes a predicted
cytoplasmic basic protein that, although considerably shorter
than the HCV core protein, may perform similar functions in
RNA binding and packaging during virus assembly. HHPgV-1
similarly resembles HCV and several other hepaciviruses in pos-
sessing numerous sites for potential N-linked glycosylation in the
predicted envelope genes, particularly E2, in which 11 N-linked
and one predictedO-linked sites are located. This pattern of heavy
glycosylation, which contrasts with the paucity of sites in HPgV
and most other pegiviruses, is believed to shield viral envelopes
fromantibody-mediated neutralization (40, 41) and to participate
in virus entry into hepatocytes (42). It is conceivable that
HHpgV-1 virions display similar host interactions.
The finding of persistent viremia in hemophiliacs in sequen-
tially collected samples and the time interval between sampling
and their previous exposure to potentially infectious clotting fac-
tor concentrates (1989 to 1990) demonstrates the propensity of
HHpgV-1 for long-term host persistence, an attribute shared with
most, if not all, hepaciviruses and pegiviruses. HHpgV-1 resem-
bles other viruses in these genera in possessing a large-scale struc-
tured RNA genome (GORS) that is tightly associated with host
persistence throughout different families of positive-stranded
mammalian RNA viruses (43, 44). Although this association is
poorly characterized functionally (45), HHpgV-1 shares mid-
rangeMFED values with other group 2 pegiviruses and with HCV
(Table 3). Future bioinformatics characterization of the configu-
ration of RNA structures in such viruses, and potentially experi-
mentally in RPgV, will be informative in furthering our under-
standing about this generic property of persistent RNA viruses.
The recent documentation of substantially greater sequence
diversity of hepaciviruses and pegiviruses and the existence ofmo-
saic features and variability in genome organizationsmay lead to a
reevaluation of the original criteria by which the generaHepacivi-
rus and Pegivirus were originally defined (22). As reviewed above,
possession of a type IV IRES does not define hepaciviruses, as this
element is present among group 2 pegiviruses (Fig. 4). Similarly,
some hepaciviruses have pegivirus-like 5=UTR sequences. Posses-
sion of a core protein may turn out to be a similarly variable
attribute, with several pegiviruses possessing coding sequences
upstream of E1 and, in the case of HHpgV-1, a potential cytoplas-
mic location that may confer a biological function analogous to
the hepacivirus core protein. Nevertheless, phylogenetic analysis
of conserved genes in the nonstructural genome region clearly
maintains separate, bootstrap-supported groupings of pegiviruses
and hepaciviruses, while the E1/E2/X structural gene block of
pegiviruses shows little or no homology with the E1 and E2 pro-
tein genes of hepaciviruses. Future characterization of these vi-
ruses in a wider range of hosts will provide more information on
the value and durability of current criteria for Hepacivirus and
Pegivirus genus assignments.
Comprehensive virome analysis helped us in the identification
of HHpgV-1, a new human virus. We note that virome analysis
also identified approximately 40% sequence reads that remained
unclassified due to their low sequence similarity to known viruses
or to any other known sequence. Viruses show remarkable diver-
sity in terms of replication-expression strategy and genomic com-
plexity (46). After acquiring the HHpgV-1 genome, we reverse
mapped it to the unclassified virome reads andnoticed that several
unclassified sequence reads were part of the HHPgV-1 genome
(core, E1, E2, NS4A, andNS4B genes). These findings suggest that
other fractions of these unclassified reads may represent unrecog-
nized highly diverse viruses or the most rapidly evolving part of
their genomes. The genomic sequence data of HHpgV-1 will be
helpful in designing molecular reagents to study its prevalence,
persistence, transmission, and disease association in humans. Be-
sides providing information regarding a new human virus infec-
tion, identification of HHpgV-1 expands our knowledge of the
origin, genetic diversity, and evolution of hepaciviruses and pegi-
viruses.
TABLE 3 Mean folding energy values of different pegivirus lineages/
groups
Group Lineage No.a MFE (kcal/mol) MFED (%)b
1 HHpgV-1 65.06 7.6
Human_PgV 10 82.78 11.7 0.7
OWM_PgV 8 73.55 10.9 1.3
NWM_PgV 3 76.08 11.8 0.4
Bat_1_PgV 6 80.54 10.6 1.6
Bat_4_PgV 4 72.99 10.2 0.7
Bat_5_PgV 1 77.15 9.7
Equine_1_PgV 1 76.08 10.4
Equine_2_PgV 1 72.31 11.9
2 Bat_2_PgV 2 77.12 7.9 0.0
Bat_3_PgV 4 72.67 8.5 0.9
Rodent_PgV 2 79.91 8.8 0.8
a Number of sequences compared.
b Mean of 225-base fragments, in 24-base increments, over the complete coding region.
Values are means and standard deviations.
FIG 6 ML phylogenetic analysis of partial NS3 sequences of HHpgV-1 vari-
ants found in different human serum samples using a rodent pegivirus se-
quence as the outgroup. Phylogenetic analysis used 100 bootstrap resamplings
to determine robustness of grouping. HHpgV-1 variants found in serum sam-
ples from the same patients are labeled on the right (tt, TTVS; m, MHCS).
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MATERIALS AND METHODS
Human samples.All human serum samples used this studywere obtained
from the NHLBI sample repository and were collected as part of two
studies, the Transfusion-TransmittedViruses Study (TTVS) and theMul-
ticenter Hemophilia Cohort Study (MHCS). The study plan and research
were approved by Columbia University Medical Center, no. IRB-
AAAN5157. TTVS samples were collected at 4 participating blood centers
distributed across the United States from July 1974 through June 1980.
The MHCS-I evaluated and prospectively followed patients with hemo-
philia or a related coagulation disorder form 1982 to 1986. Adults and
children who had a congenital coagulation disorder (hemophilia A or B
[congenital factor VIII or IX deficiency]), von Willebrand’s disease, or
another disorder were enrolled from 8 collaborating hemophilia centers
in the United States between 1982 and 1985. Four additional centers from
the United States and 4 centers from Europe joined the study between
1987 and 1990. In MHCS-I, subjects were evaluated semiannually with a
standardized physical examination, abstraction of medical records, and
phlebotomy (4–8).
Virome amplification, sequencing, and bioinformatic analysis. Se-
rum samples were filtered through a 0.45-m filter and treated with nu-
cleases to digest free nucleic acids (NAs) for enrichment of viral NA and
then extracted in NucliSens buffer using the automated easyMAG system
(bio-Mérieux, United States). Total RNA extracts were reverse tran-
scribed using a SuperScript III kit (Invitrogen Life Technologies) with
random hexamer primers. The cDNA was RNase H treated prior to
second-strand DNA synthesis using Klenow fragment (3=–5= exonuclease
negative) (New England Biolabs). The double-stranded cDNA was
sheared to a 200-bp average fragment length using a Covaris E210 focused
ultrasonicator. Sheared DNA was purified and used for Illumina library
construction using a Kapa library preparation kit (KK8234; Kapa Biosys-
tems) and SeqCap EZ Library SR (Nimblegen, Roche). The sequencing
libraries were quantified using an Agilent Bioanalyzer 2100. Samples with
low concentrationswere amplified by increasing PCR cycle numbers from
9 to 14. All sequencing was done on the Illumina HiSeq 2500 platform
(Illumina, San Diego, CA, USA), yielding an average of 150 million reads
per sequencing lane. Virome analysis included only those sequences
that were most closely related to vertebrate viruses and was done using
MEGAN version 5.10.5 (47). Sequence data were demultiplexed using
Illumina software to generate FastQ files for individual samples. Se-
quences were filtered using Q30 and mapped against reference genomes
from GenBank with Bowtie2 mapper 2.0.6 (http://bowtie-bio.sourceforge.net).
SAMtools (v 0.1.19) were used to generate the consensus genomes and
coverage statistics. Integrative Genomics Viewer (v 2/3/55; Broad Insti-
tute) was used to generate the sequence coverage plots. Host-derived se-
quences were identified using Bowtie2-based sequence mappings against
the reference host genomes downloaded from the NCBI database. Se-
quencing data obtained from the clinical samples were preprocessed using
PRINSEQ (v 0.20.2) software, and primer-trimmed, quality score-filtered
reads were aligned against the host reference databases to remove the host
background. The host-subtracted sequence reads were de novo assembled
using MIRA (v 4.0) or SOAPdenovo2 (v 2.04) assemblers, and then con-
tigs and unique single sequences were subjected to a homology search
usingMegaBlast against theGenBank nucleotide database. Sequences that
showed poor or no homology at the nucleotide level were subjected to a
search with BLASTx against the viral GenBank protein database. Viral
sequences from BLASTx analysis were subjected to another round of
BLASTx homology search against entire GenBank protein database to
correct for biased E values due to the smaller size of the virus-only data-
base, and taxonomy was reassigned. Based on the contigs identified for
different viral strains, GenBank sequences were downloaded and used for
mapping the whole data set to recover partial or complete genomes. The
descriptive statistics mean, standard deviation (SD), and median were
calculated for viral count and viral rate. The pretransfusion viral rate and
the posttransfusion rate were compared by paired Wilcoxon rank sum
test.
Screening assays of HHpgV-1. The polyprotein and UTR of
HHpgV-1 were aligned to all known hepaciviruses and pegiviruses. Nu-
cleotide and amino acid motifs showing relative conservation among dif-
ferent virus lineages were used to make primers for screening of samples
forHHpgV-1 and related variants. All PCRmixtures usedAmpliTaqGold
360 master mix (catalog no. 4398881; Applied Biosystems) and 2 l of
cDNA. The HHpgV-1 helicase gene heminested PCR assay used primer
pair HHpgV-ak1 (5=-GTTGTATTCGCCACAGCCAC-3=) and HHpgV-
ak2 (5=-TCAAAGTTTCCTGTGTAGCCTGT-3=) in the first round of
PCR and the pair HHpgV-ak3 (5=-GTATTCGCCACAGCCACTCC-3=)
andHHpgV-ak2 in the second round of PCR. For the first round, the PCR
cycle included 8 min of denaturation at 95°C, 10 cycles of 95°C for 40 s,
56°C for 1 min, and 72°C for 1 min, 30 cycles of 95°C for 30 s, 55°C for
1 min, and 72°C for 1 min, and a final extension at 72°C for 5 min. In first
10 cycles, the annealing temperature was ramped down by 0.5°C each
cycle to allow mutation tolerance during primer hybridization. For the
second round, PCR conditions included 8min of denaturation at 95°C, 10
cycles of 95°C for 40 s, 60°C for 1 min, and 72°C for 1 min, 30 cycles of
95°C for 30 s, 56°C for 1 min, and 72°C for 1 min, and a final extension at
72°C for 5 min. The hepatitis C virus PCR assay used the primer pair
HCV-ak-F1 (5=-GCGCCCATCACGGCITAYGC-3=) and HCV-ak-R1
(5=-GTCTTGGTCCACRTTGGTRTACAT-3=) in the first round of PCR
and the pair HCV-ak-F2 (5=-GCCCATCACGGCGTAYGCNCARCA-3=)
and HCV-ak-R2(5=-CTTGGTCCACRTTGGTRTACATYTG-3=) in the
second round of PCR. For the first round, the PCR cycle included 8min of
denaturation at 95°C, 10 cycles of 95°C for 40 s, 58°C for 1 min, and 72°C
for 45 s, 30 cycles of 95°C for 30 s, 55°C for 1 min, and 72°C for 45 s, and
a final extension at 72°C for 5 min. In the first 10 cycles, the annealing
temperature was ramped down by 0.5°C each cycle to allow mutation
tolerance during primer hybridization. For the second round, PCR con-
ditions included 8 min of denaturation at 95°C, 10 cycles of 95°C for 40 s,
64°C for 1 min, and 72°C for 45 s, 30 cycles of 95°C for 30 s, 59°C for 30 s,
and 72°C for 40 s, and a final extension at 72°C for 5 min. The
GBVc-NS3 PCR assay used the primer pair GBVc-ak-F1 (5=-
CCTTGGACCCAGGTICCNACIGA-3=) and GBVc-ak-R1 (5=-CCTGGT
GGGGTRGCIGTNGC-3=) in the first round of PCR and the pair GBVc-
ak-F2 (5=-GGACCCAGGTGCCIACGGAYGC-3=) and GBVc-ak-R2 (5=-
CCTGGTGGGGTRGCGGTNGCRTA-3=) in the second round of PCR.
For the first round, the PCR cycle included 8min of denaturation at 95°C,
10 cycles of 95°C for 40 s, 63°C for 1 min, and 72°C for 30 s, 30 cycles of
95°C for 30 s, 60°C for 1 min, and 72°C for 40 s, and a final extension at
72°C for 5 min. In first 10 cycles, the annealing temperature was ramped
down by 0.5°C each cycle to allow mutation tolerance during primer
hybridization. For the second round, PCR conditions included 8 min of
denaturation at 95°C, 10 cycles of 95°C for 40 s, 71°C for 1 min, and 72°C
for 30 s, 30 cycles of 95°C for 30 s, 64°C for 30 s, and 72°C for 40 s, and a
final extension at 72°C for 5 min.
Phylogenetic and RNA secondary structure analysis.Nucleotide se-
quences (5= UTRs) and translated protein sequences (coding regions)
were aligned using the program MUSCLE as implemented in the SSE
package (37). Sequence divergence scans were performed, and summary
values for different genome regions were generated by the program Se-
quence Distance in the SSE package. Bootstrapped maximum-likelihood
trees for the NS3 helicase region and NS5B polymerase regions were con-
structed using the maximum-likelihood algorithm as implemented in
MEGA, using the optimalmodel selected byModel Test. For both regions,
this was the Le-Gascuel model with a gamma distribution (5 rates) and
invariant sites (LG    I). Phylogenetic analysis of NS3 nucleotide
sequences was performed similarly using the Jukes-Cantor substitution
model (selected by Model Test for this data set).
RNA structures were predicted by Mfold and by homology searching
and structural alignment with bases conserved in other hepaciviruses.
Structure prediction for the pseudoknot region inHCV (IIIf) and homol-
ogous pairings in other hepaciviruses could not be predicted by Mfold or
other conventional RNA secondary-structure prediction algorithms.
Kapoor et al.
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Structure predictions upstream of stem-loop III were performed by
Mfold.
Cleavage sites between HHpgV-1 structural proteins were predicted
using the SignalP version 4.1 program (16); these were concordant with
positions predicted from the sequence alignment. Cleavage between non-
structural genes was predicted by alignment of the NS2/NS3, NS3/4A,
NS4A/4B, NS4B/5A, and NS5A/5B sites previously proposed for simian
pegiviruses (18).
HHpgV-1 and other pegivirus sequences were analyzed for the pres-
ence of GORS by comparing folding energies of consecutive fragments of
nucleotide sequence with random sequence order controls using the pro-
gram’s MFED scan in the SEE package (37). Minimum folding energies
(MFEs) of rodent virus genomes were calculated by using the default
setting in the programZipfold.MFE results were expressed asMFEDs, i.e.,
the percentage difference between the MFE of the native sequence from
that of the mean value of the 50 sequence order-randomized controls
(32).
Nucleotide sequence accession number. The complete genome of
HHpgV-1 has been submitted to GenBank under accession number
KT439329.
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